Efficacy Makes Sacituzumab Govitecan ‘Attractive’ in Advanced Breast Cancer

An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.

Data from the phase 3 TROPiCS-02 trial (NCT03901339) indicated that sacituzumab govitecan (Trodelvy) yielded various improvements in efficacy compared with chemotherapy in patients with hormone receptor (HR)-positive, HER2-negative breast cancer.

CancerNetwork® spoke with Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, in Boston, ahead of the FDA’s approval of sacituzumab govitecan about data supporting the agency’s action.1

In the TROPiCS-02 trial, there was a median progression-free survival (PFS) of 5.5 months (95% CI, 4.2-7.0) in the sacituzumab arm compared with 4.0 months (95% CI, 3.1-4.4) in the chemotherapy arm (HR, 0.789; 95% CI, 0.646-0.964; P = .02).2 Additionally, the median overall survival (OS) was 14.4 months vs 11.2 months in each respective cohort (HR, 0.789; 95% CI, 0.646-0.964; P = .02).3

Tolaney noted the value of the improvements made in efficacy among patients treated with sacituzumab. “[The data] makes [sacituzumab] a really attractive agent for this patient population,” she said.


TROPiCS-02 had really explored sacituzumab govitecan in patients who were very heavily pretreated. They had had a prior CDK4/6 inhibitor, they had had a minimum of 2 lines of chemotherapy in the advanced disease setting, and could have received up to 4 lines of chemotherapy, so they had a median of 3 [lines of chemotherapy previously received]. [Patients were] very heavily pretreated, and patients had been randomized to get sacituzumab or to get treatment of physician's choice chemotherapy. What we saw was that sacituzumab not only improved progression-free survival but, in fact, led to statistically significant improvement in overall survival, as well as significant improvement in objective response rate. What we're seeing is that this agent does perform better than chemotherapy in this population all around in terms of response, PFS, and OS. And so I think it makes it a really attractive agent for this patient population.


  1. U.S FDA approves Trodelvy in pre-treated HR+/HER2- metastatic breast cancer. News release. Gilead. February 3, 2023. Accessed February 3, 2023. https://bwnews.pr/3Y0bftX
  2. Rugo HS, Bardia A, Marme F, et al. Sacituzumab govitecan in in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2022;40(29):3365-3376. doi:10.1200/JCO.22.01002
  3. Rugo HS, Bardia A, Marme F, et al. Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). Ann Oncol. 2022;33(suppl 7):S808-S869. doi:10.1016/annonc/annonc1089
Related Videos
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.
Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.
At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.
Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.
Related Content